TrichoTest™ | 2024 Utilising SNP Association Analysis as a Prospective Approach for Personalising Androgenetic Alopecia Treatment Francès MP, Vila-Vecilla L, Valentina Russo, Polonini HC, de Souza GT Dermatology and Therapy, 1-11. This study focuses on correlating the genetic mechanisms of Androgenetic alopecia (AGA) with molecular targets involved in the response to current treatment modalities. An anonymised database including 26,607 patients was subjected to analysis. The study establishes a preliminary association between eight specific SNPs and AGA. These genetic markers offer insights into the variability of therapeutic responses, thus underlining the importance of personalised treatment approaches. Read more SEE PRODUCT
TrichoConcept | 2024 Clinical Safety Profile of TrichoConcept™, a Line of Cosmetic Vehicles for Personalized Treatment of Alopecia Marianni B, Polonini HC, Silva C International Journal of Pharmaceutical Compounding, 2024, volume 28 (2), pages 169-175 Alopecia is a chronic dermatological disorder that affects patients worldwide, with a significant impact on quality of life, self-esteem, and psychological wellbeing. The purpose of this study was to examine the irritation, skin sensitization, photoallergy, and phototoxicity potential of a line of ready-to-use vehicles, TrichoConcept™. The results of this study, it is suggested that the investigated products can be considered safe under the evaluated conditions, and the claims “dermatologically tested”, “clinically tested”, and “nonirritant” can be supported. Read more SEE PRODUCT
TrichoConcept | 2024 Compatibility of Caffeine, Clobetasol, Propionate, Dutasteride, Nicotinamide and Progesterone in TrichoFoam™, a Natural Vehicle for Hair Foams Polonini HC, de Sousa PL, Silva Carolina CV, Marianni B International Journal of Pharmaceutical Compounding, 2024, volume 28 (2), pages 161-168 Alopecia is a chronic dermatological disorder affecting men and women worldwide. The purpose of this study was to assess topical foams’ physicochemical and microbiological stabilities of formulations compounded with TrichoFoam™ as the ready-touse vehicle. For the conclusion the stability of the active pharmaceutical ingredients from different pharmacological classes with TrichoFoam™, suggesting that this vehicle can be an excellent alternative for personalized alopecia treatment. Read more SEE PRODUCT
InvoMatic | 2023 Development of an immediate release excipient composition for 3D printing via direct powder extrusion in a hospital Rosch M, Gutowski T, Baehr M, Eggert J, Gottfried K, Gundler C, Nürnberg S, Langebrake C, Dadkhah A International Journal of Pharmaceutics, 643, 123218 The goal of the study was to present a possible option for the implementation of 3D-printed tablets into the digital Closed Loop Medication Management system; the required tablet formulation and development of the manufacturing process, as well as the pharmaceutical validation, were conducted. As a result, the developed method is suitable for the implementation of Closed-Loop Medication Management systems in hospital pharmacies and could, therefore, contribute to medication safety. Read more
Syrspend SF | 2023 Compatibility of Commonly Used Active Pharmaceutical Ingredients in a Ready-to-Use Oral Suspending Vehicle Mansourian M, Dijkers E, Silva CV, Polonini HC Pharmaceutics 2023, 15(10), 2388 The present study evaluated the stability of amoxicillin trihydrate (50 mg/mL), clozapine (25 mg/mL), indomethacin (5.0 mg/mL), levodopa/carbidopa (10.0/2.5 mg/mL), levothyroxine sodium (T4, 25 µg/mL), lomustine (4.0 and 10.0 mg/mL), methyldopa (25 mg/mL) and procarbazine (10.0 mg/mL) in SyrSpend® SF PH4. The study demonstrated promising stability for the compounded suspensions, as all APIs exhibited stability throughout the study duration and met content uniformity criteria. Read more SEE PRODUCT
TrichoConcept | 2023 Compounded Hair Solutions and Foams Containing Minoxidil: Does the Color Change Impact Stability? Polonini HC, Silva CV Scientia Pharmaceutica, 91 (3), 39. This study aimed to assess the physical–chemical, and microbiological stability and investigate the color change of compounded minoxidil formulations in TrichoSolTM or TrichoFoamTM. HPLC analyses and antimicrobial effectiveness testing were conducted in concentrations from 1.0% to 7.0% of minoxidil. The color change was noticeable, but no other quality attribute was affected. No precipitation was observed, and the pH was relatively stable. Read more SEE PRODUCT
Biosil® | 2023 Choline-stabilized orthosilicic acid, applications of an oral supplement in dermatology Gaviglio MR, Calomme MR Journal of Plastic and Pathology Dermatology 2023, volume 19 (1), pages 17-29 Several clinical trials have investigated the use of choline-stabilized orthosilicic acid as an oral supplement to improve the quality of skin, hair and nails. The present article discusses the potential use of ch-OSA® as an oral supplement in dermatology, its mechanisms of action and other health benefits outside the field of dermatology. For the conclusion, the intake of the choline containing ch-OSA® complex, contributes to a healthy homocysteine metabolism and protects collagen against homocysteine mediated denaturation. Read more
TrichoConcept | 2023 Growth factors in trichology: mechanism of action and real-life experience of the ADECA group – Trichology and Annexes Vitiello A, Trischitta A, Gaudiello F, Pezza M, Russo I, Ceddia C, Villa L, Casula L, Ginepri A Journal of Plastic and Pathology Dermatology 2023, volume 19 (3), pages 133-140 Telogen effluvium is a scalp disorder characterized by excessive and diffuse hair loss that is not associated with scarring. One of the goals for the treatment of telogen effluvium is to stop hair loss by reducing the percentage and the number of telogen hair in favor of anagen hair and lengthening the duration of this phase. The objective of this study was to evaluate the effects of daily administration of 1 ml of a galenic lotion based on bioidentical growth factors, latanoprost, NADPP (Nicotinic acid adenine dinucleotide phosphate), every day for at least 5 months. The results indicate that a regression of telogen effluvium was achieved with a significant increase in hair regrowth and a strong decrease in hair loss in almost all treated patients. Read more SEE PRODUCT
NutriGen™ | 2023 Genetic variant panel allows predicting both obesity risk, and efficacy of procedures and diet in weight loss Mera-Charria A, Nieto-Lopez F, Francès MP, Arbex PM, Vila-Vecilla L, Russo V, Vicente Silva CC, De Souza GT Frontiers in Nutrition, 10 Obesity is a multifactorial condition with a relevant genetic correlation. Recent advances in genomic research have identified several single nucleotide polymorphisms (SNPs) in genes such as FTO, MCM6, HLA, and MC4R, associated with obesity. This study aimed to evaluate the association of 102 SNPs with BMI and weight loss treatment response in a multi-ethnic population. Read more SEE PRODUCT
ImunoTF | 2023 Transfer factors peptides (Imuno TF®) modulate the lung inflammation and airway remodeling in allergic asthma Oliveira CR, Carvalho J, Olímpio F, Vieira R, Aimbire I, Polonini HC Frontiers in Immunology, 13, 7606 The equilibrium between cytokines as well as transcription factors associated to Th2, Th1, and Treg cells is compromised in allergic asthma. Imuno TF® is a food supplement with ability to interfere in immune system pathways. It has been previously demonstrated that Imuno TF® upregulated Th1 cell response whilst downregulated Th2 cell response in human lymphocytes. Read more SEE PRODUCT